Company: WHWK
Filing Date: 2025-02-05
Form Type: DEFA14A
Source: 0001193125-25-020865
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-02-05
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

AADI BIOSCIENCE, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11.                                                          |

Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025

Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated
Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio

Aadi’s Board Recommends Stockholders Vote “FOR” All Proposals to Support the Company’s Business Transformation

Company Expects to Close Transactions in the First Quarter of 2025, Subject to Stockholder Approval and Other Closing Conditions

MORRISTOWN, NJ, Feb. 5, 2025 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI) (“Aadi” or the “Company”) announced it filed
its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) on January 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the Company’s
upcoming Special Meeting of Stockholders (the “Special Meeting”) which is scheduled to be held on February 28, 2025.

The Company’s
strategic plan, which was first announced in December 2024, includes three